Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $51.24 Million Position in Johnson & Johnson $JNJ

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 266,205 shares of the company’s stock after selling 3,529 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Johnson & Johnson were worth $51,237,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. SOA Wealth Advisors LLC. boosted its stake in Johnson & Johnson by 0.7% in the third quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock valued at $1,371,000 after buying an additional 53 shares in the last quarter. Ethos Financial Group LLC grew its holdings in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock valued at $1,689,000 after purchasing an additional 53 shares during the last quarter. Heritage Oak Wealth Advisors LLC increased its position in Johnson & Johnson by 3.5% during the 3rd quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company’s stock worth $304,000 after purchasing an additional 55 shares in the last quarter. Lifestyle Asset Management Inc. lifted its stake in Johnson & Johnson by 3.4% in the 3rd quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company’s stock valued at $312,000 after purchasing an additional 56 shares during the last quarter. Finally, Wynn Capital LLC boosted its position in Johnson & Johnson by 0.4% in the third quarter. Wynn Capital LLC now owns 15,930 shares of the company’s stock valued at $2,954,000 after buying an additional 57 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 2.3%

Shares of Johnson & Johnson stock opened at $218.53 on Thursday. The firm has a market cap of $526.51 billion, a price-to-earnings ratio of 21.09, a PEG ratio of 2.19 and a beta of 0.34. Johnson & Johnson has a one year low of $141.50 and a one year high of $218.86. The stock’s 50-day moving average is $204.52 and its 200 day moving average is $186.04. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 14th. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.76 by $0.04. The company had revenue of $23.99 billion during the quarter, compared to analyst estimates of $23.73 billion. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Johnson & Johnson’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.42 EPS. Equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Phase 3 MajesTEC-9 topline: TECVAYLI (teclistamab) monotherapy showed a 71% reduction in risk of progression or death and a 40% reduction in risk of death versus standard of care in early-relapse, largely anti‑CD38/lenalidomide‑refractory myeloma — a potentially significant new earlier-line oncology opportunity that can drive revenue and R&D upside. TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
• Positive Sentiment: Delaware court orders recalculation of damages in Auris/robotics case — the state’s top court overturned part of a ~$1B award and ordered a recalculation that could materially reduce J&J’s payout exposure, lowering legal risk on the balance sheet. Court Orders Recalculation Of Damages In Johnson & Johnson Auris Case
• Positive Sentiment: MedTech momentum: Zacks highlights growth driven by cardiovascular strength and new product rollouts, supporting the MedTech segment’s contribution even as China weakness lingers — a constructive signal for recurring revenue. What’s Powering J&J’s MedTech Growth Ahead of Q4 Release?
• Positive Sentiment: Psychiatry pipeline/data: New CAPLYTA and SPRAVATO analyses being presented at ACNP reinforce J&J’s CNS franchise and could support future label or adoption upside. Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
• Neutral Sentiment: Company expected to report quarterly results this week — keep an eye on guidance, MedTech trends and margins; earnings timing may create short-term volatility but is routine. Johnson & Johnson (JNJ) Projected to Post Quarterly Earnings on Wednesday
• Neutral Sentiment: Investor attention spikes: Zacks notes heavy search/interest in JNJ — increased attention can amplify moves around data and earnings. Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
• Neutral Sentiment: Dividend visibility: JNJ features in dividend-focused lists (Dogs of the Dow coverage); this underpins income investor interest but is unlikely to move shares materially on its own. The Dogs of the Dow: 10 Downtrodden Dividends Paying Out Up to 6.8%
• Negative Sentiment: Zacks preview flags J&J may lack the setup for an earnings beat next week — if results or guidance disappoint, that could reverse some of today’s gains. Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth

Analyst Ratings Changes

A number of brokerages have issued reports on JNJ. Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Loop Capital set a $190.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Royal Bank Of Canada set a $240.00 price target on shares of Johnson & Johnson in a research report on Wednesday, December 17th. Finally, Wells Fargo & Company lifted their price target on shares of Johnson & Johnson from $212.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $213.33.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.